Literature DB >> 21533319

Long-term survival after transarterial chemoembolization for hepatocellular carcinoma.

M Iozzino1, E Spaziani, M Picchio, A Saltarelli, A Di Filippo, F De Angelis, F Narilli, F Stagnitti, R Cianni.   

Abstract

Hepatocellular carcinoma is a main challenge in oncologic care. Surgery is the mainstay of treatment. Transarterial chemoembolization is the most widely used palliative treatment for hepatocellular carcinoma. The Authors present a case report of a 61-year old man with hepatocellular carcinoma, belonging to Child-Pugh class A. The advanced age and the previous history of bladder carcinoma made the patient not suitable for liver transplantation. The patient refused hepatic resection so that transarterial chemoembolization was proposed. During 14-year follow-up there was intrahepatic progression of the tumor after the first treatment, followed by reduction in size and number of the lesions after subsequent treatments. In spite of the ominous prognosis of hepatocellular carcinoma, in this case-report transarterial chemoembolization allowed us to achieve a unique long-term survival.

Entities:  

Mesh:

Year:  2011        PMID: 21533319

Source DB:  PubMed          Journal:  Clin Ter        ISSN: 0009-9074


  1 in total

1.  Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Guosheng Yuan; Yuchen Zhou; Hao Zhang; Junjie Wang; Nianhuan Yang; Yabing Guo; Dinghua Yang; Yuanping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.